Detection method of rosiglitazone or pioglitazone in Chinese patent medicine and health food

Abstract

The invention relates to a detection method for qualitatively detecting whether thiazolidinedione medicines are doped in a Chinese patent medicine and a health food which have a hypoglycemic effect. The method comprises the following steps: 1, taking a sample to be measured, adding dichloromethane according to a case that 5-10mL of dichloromethane corresponds with 1g of the sample, strongly shaking for at least 40s, and filtering; 2, adding a small amount of a hydrochloric acid solution with the concentration of 0.08-0.12mol / L to a filtrate obtained in step 1, up-down overturning at least eight times, and standing for two-phase layering; and 3, adding a proper amount of a phosphomolybdic acid solution with the concentration of 0.04-0.1g / mL to an upper layer obtained in step 2 drop by drop. If deposition or turbidity appears, it shows that rosiglitazone or pioglitazone is doped in the sample. A corresponding kit comprises a reagent 1: dichloromethane; a reagent 2: the hydrochloric acid solution with the concentration of 0.08-0.12mol / L; and a reagent 3: the phosphomolybdic acid solution with the concentration of 0.04-0.1g / mL. The detection method of the invention has the advantages of accuracy and reliability, and the kit is convenient for carrying and carrying out onsite detection.

Description

technical field [0001] The present invention relates to a method for qualitatively detecting the presence or absence of chemical substances, in particular to whether Chinese patent medicines and health foods with hypoglycemic effects are doped with thiazolidinediones, mainly rosiglitazone or pioglitazone. Detection method. Background technique [0002] There are many drugs for the treatment of diabetes. In the early 1980s, chlorpropamide and tolbutamide were often used, and later developed into many categories. Existing drugs for the treatment of diabetes can be roughly divided into five categories, namely sulfonylurea drugs, biguanide drugs, α-glucosidase inhibitors, thiazolidinediones (TZD) drugs and non-sulfonylurea insulin secretagogues . The toxic and side effects shown after taking these chemical drugs reach a certain amount are just very obvious, as: oral hypoglycemic drug rosiglitazone or pioglitazone (especially overdose) may have the risk of raising the patient's...

AI Technical Summary

Problems solved by technology

This is mainly due to the following reasons: First, the chemical alkalinity of the doped rosiglitazone and pioglitazone is very weak. If no special extraction and separation steps are taken, although these hypoglycemic compounds can react with the precipitant, they will coexist in the product Other alkaline components in the product will also react, covering up the desired reaction phenomenon, resulting in unclear and unclear results, making it difficult to make accurate judgments

Second, the addition of hypoglycemic ingredients may be a combination of various types. For example, thiazolidinediones may be added in combination with sulfonylureas and biguanides, or sulfonylureas and biguanides may be added separately. It will interfere with the detection and display, and there will be false positives for thiazolidinediones; that is, even if the test is positive, it cannot be judged whether it is rosiglitazone or pioglitazone

However, according to the teaching of this patent technology, in an ethanol environment (as the technical solution of claim 1) or in a non-acidic, non-neutral environment for detection (as described in the penultimate paragraph on page 2 of its specification), the result The error is also extremely obvious (the test result is verified by mass-liquid chromatography technology, and the correct rate is less than 40%)

Images